ID   M243
AC   CVCL_D752
DR   cancercelllines; CVCL_D752
DR   Cosmic; 1459663
DR   Cosmic; 1665004
DR   Wikidata; Q54903559
RX   PubMed=20689758;
RX   PubMed=22515704;
RX   PubMed=25645078;
CC   Sequence variation: Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Asp32Tyr (c.94G>T); ClinVar=VCV000017581; Zygosity=Unspecified (PubMed=25645078).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Homozygous (PubMed=25645078).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Glu353Gly (c.1058A>G) (p.Glu156Gly, c.467A>G); ClinVar=VCV000237638; Zygosity=Heterozygous (PubMed=25645078).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 8
//
RX   PubMed=20689758; DOI=10.1593/neo.10414; PMCID=PMC2915408;
RA   Tap W.D., Gong K.-W., Dering J., Tseng Y., Ginther C., Pauletti G.,
RA   Glaspy J.A., Essner R., Bollag G., Hirth P., Zhang C., Slamon D.J.;
RT   "Pharmacodynamic characterization of the efficacy signals due to
RT   selective BRAF inhibition with PLX4032 in malignant melanoma.";
RL   Neoplasia 12:637-649(2010).
//
RX   PubMed=22515704; DOI=10.1186/1476-4598-11-22; PMCID=PMC3444881;
RA   von Euw E.M., Atefi M., Attar N., Chu C., Zachariah S., Burgess B.L.,
RA   Mok S., Ng C., Wong D.J.L., Chmielowski B., Lichter D.I., Koya R.C.,
RA   McCannel T.A., Izmailova E., Ribas A.;
RT   "Antitumor effects of the investigational selective MEK inhibitor
RT   TAK733 against cutaneous and uveal melanoma cell lines.";
RL   Mol. Cancer 11:22.1-22.9(2012).
//
RX   PubMed=25645078; DOI=10.1186/s12943-015-0293-5; PMCID=PMC4320814;
RA   Atefi M., Titz B., Avramis E., Ng C., Wong D.J.L., Lassen A.,
RA   Cerniglia M., Escuin-Ordinas H., Foulad D., Comin-Anduix B.,
RA   Graeber T.G., Ribas A.;
RT   "Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.";
RL   Mol. Cancer 14:27.1-27.12(2015).
//